Is Non-Invasive genetic Prenatal Testing ready for use ? The evidence, the costs and the ethics addressed in a HTA with recommendations for practice and for research

<u>L Ballini</u>, A Negro, S Maltoni, V Basevi, M Camerlingo, L Vignatelli, F Trimaglio Agenzia Sanitaria e Sociale Regionale



The Working Group

ACCORSI Paolo BATTAGLIARIN Giuseppe BORSARI Silvana CALABRESE Olga **CANESTRARI** Stefano **DALLA CASA Paola DAZZANI** Carla **FACCHINETTI Fabio FRUSCA** Tiziana **GRECO** Pantaleo

INCERTI MEDICI Cristina LALATTA COSTERBOSA Marina LENZI Marinella **RIZZO Nicola ROZZI** Elisa **SANDRI Fabrizio** SANTUCCI Sandra **STAGNI** Maria Grazia **TRENTI** Tommaso **ZOLI Silvia**









Background

Prenatal screening in Emilia-Romagna region

- offered to all pregnant women and
- based on combined test (nuchal translucency + β-HCG + PAPP-A) performed between 10⁺⁰ and 14⁺¹ weeks of gestation

Non Invasive Prenatal Tests (NIPT)

Calculate risk of aneuploidy using cell-free foetal DNA (cffDNA) extracted from maternal blood.

cffDNA is amplified and sequenced (by different techniques)* and risk of aneuploidy elaborated by specific algorithms

* massive parallel sequencing (MPS), targeted sequencing, single nucleotide polymorphisms (SNPs)


HTA + Recommendations on NIPT requested by Policy Maker





Methods – GRADE

- Policy question
- Multidisciplinary panel (n.20)
- Definition of research questions and voting of importance of outcomes (GRADE)
- Literature review + synthesis of results
- 2 rounds of voting for recommandations



+ 7 methodologists



First meeting: Research Questions

Question 1

 NIPT in <u>replacement</u> of Combined test

Question 2

 NIPT in <u>add-on</u> for positive at Combined test (cut off 1/250)

Question 3

 NIPT in <u>add-on</u> for <u>risk</u> 1/1000 -1/100 at Combined test



Second Meeting: Outcomes

1. Replacement	Vote	2. Add on + (cut off 1/250)	Vote	3. Add on -1/100-1/1000	Vote
True Positive	8	True Positive	8	True Positive	8
False Negative	8	False Negative	8	False Negative	8
True Negative	8	True Negative	8	True Negative	7
False Positive	7	False Positive	8	False Positive	8
\downarrow Invasive tests	8	↓ Invasive tests	8	↓ Invasive tests	8
↓ miscarriages/adverse events of invasive test	8	↓ miscarriages/adverse events of invasive test	8	↓ miscarriages/adverse events of invasive test	8
↓% end diagnostic process beyond 15 weeks	8	↑ % end diagnostic process beyond 15 weeks	7	↑% end diagnostic process beyond 15 weeks	7
↓ anxiety)	6	↑ anxiety	7	↑ anxiety	6
Test failure	4	Test failure	4	Test failure	4
↓ Complexity of diagnostic process	7	↑ Complexity of diagnostic process	7	↑ Complexity of diagnostic process	6
↑ Costs	4,5	↑ Costs	5	↑ Costs	4.5
↓ Costs	4	↓ Costs	4	↓ Costs	4.5

Results: diagnostic accuracy

Q 1	NIPT	Combined test
sensitivity	99.43% (97.43%-99.87%)	85%
specificity	99.91% (99.80%-99.95%)	95%
NUDT		

NIPT

Study	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Bianchi 2014	1.00 [0.59, 1.00]	1.00 (0.99, 1.00)		
Comas 2014	1.00 [0.40, 1.00]	1.00 (0.99, 1.00)		
Dan 2012	1.00 [0.98, 1.00]	1.00 [1.00, 1.00]		•
Lau 2014	1.00 [0.81, 1.00]	1.00 [1.00, 1.00]		
Norton 2015	0.98 (0.89, 1.00)	1.00 [1.00, 1.00]	-	
Pergament 20	0.99 [0.94, 1.00]	1.00 (0.99, 1.00)	1	•
Quezada 2015	0.91 [0.80, 0.98]	1.00 (0.99, 1.00)	-+	
Shaw 2014	1.00 [0.85, 1.00]	1. 00 (0.98, 1.00)		•
Song 2013	1.00 [0.72, 1.00]	1.00 [1.00, 1.00]		•
Zhang 2015	0.99 [0.98, 1.00]	1.00 [1.00, 1.00]		

Combined test

Study	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% Cl)	
Bianchi 2014	1.00 [0.40, 1.00]	0.96 [0.95, 0.97]		•	
Norton 2015	0.78 [0.64, 0.88]	0.94 [0.94, 0.94]		•	
Quezada 2015	0.91 [0.80, 0.98]	1.00 [0.99, 1.00]	-+		l i i i i i i i i i i i i i i i i i i i
Song 2013	0.55 [0.23, 0.83]	0.86 [0.84, 0.88]			
			0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1	

Q2	sensitivity		98.05 (96.79	% 9%-99.31%)	
	specificity		99.91 (99.84	% 1%-99.98%)	
Study Liang 2013 Nicolaides 2013 Norton 2012 Porreco 2014 Song 2015 Stumm 2014 Verweij 2013	Sensiti vity (95% CI) 1.00 (0.94, 1.00) 1.00 (0.88, 1.00) 0.99 (0.95, 1.00) 0.97 (0.94, 0.99) 1.00 (0.40, 1.00) 0.95 (0.84, 0.99) 0.94 (0.73, 1.00)	1.00 1.00 1.00 1.00 1.00 1.00	[0.98, 1.00] [0.98, 1.00] [1.00, 1.00] [1.00, 1.00] [0.98, 1.00] [0.99, 1.00] [0.99, 1.00]	Sensitivity (95% CI)	Specificity (95% CI)
				0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1


Q3: NO DATA (studies ongoing)




Results : costs

NIPT in Replacement: impact on budget

Q1.Replacement



Q2.add-on



NIPT in Add-on: impact on budget

OSLO HTAI 2015 12th Annual Meeting

Q3: no data



Summary of Findings Q1: replacement NIPT VS CT

Outcome	N of studies	Study design	Limitations	Indirectness	Inconsistency	Imprecision	Reporting bias	Final quality	Effect per 40 000 # NIPT CT	Importance
True Positive	10	Cross sectional	Low	Medium*	None	None	Unlikely	Moderate ⊕⊕⊕	139 119	CRITICAL
False Negative	10	Cross sectional	Low	Medium*	None	None	Unlikely	Moderate ⊕⊕⊕	1 21	CRITICAL
True Negative	10	Cross sectional	Low	Medium*	None	None	Unlikely	Moderate ⊕⊕⊕	39 824 37 867	CRITICAL
False Positive	10	Cross sectional	Low	Medium*	None	None	Unlikely	Moderate ⊕⊕⊕	36 1993	CRITICAL
Test Failure	10	Cross sectional	Low	Low	None	None	Unlikely	High ⊕⊕⊕⊕	1,5%	IMPORTANT
↓ Invasive tests	1	ITS	High**	-	-	-	-	Very low ⊕	-0,3%	CRITICAL
Costs	6	Compar ative	Low	High ***	None	High***	Unlikely	Low ⊕⊕	Increase	IMPORTANT
↓ miscarriages/adverse events of invasive test										CRITICAL
↓% end diagnostic process beyond 15 weeks										CRITICAL
↓ anxiety) ↓ Complexity of	-	-	-	-	-	-	-	-	-	IMPORTANT
diagnostic process										CRITICAL

Prevalence 0,349%

* 3 studies with high prevalence of high risk population

** Before and after study reanalysed as ITS

*** High variability in costs




Summary of Findings Q2: NIPT add on

Outcome	N of studies	Study design	Limitations	Indirectness	Inconsistency	Imprecision	Reporting bias	Final quality	Effect per 2112 CT positive #	Importance
True Positive	7	Cross sectional	Low	Medium*	None	None	Unlikely	Moderate ⊕⊕⊕	117	CRITICAL
False Negative	7	Cross sectional	Low	Medium*	None	None	Unlikely	Moderate ⊕⊕⊕	2	CRITICAL
True Negative	7	Cross sectional	Low	Medium*	None	None	Unlikely	Moderate ⊕⊕⊕	1991	CRITICAL
False Positive	7	Cross sectional	Low	Medium*	None	None	Unlikely	Moderate ⊕⊕⊕	2	CRITICAL
Test Failure	7	Cross sectional	Low	Low	None	None	Unlikely	High ⊕⊕⊕⊕	4.6%	IMPORTANT
↓ Invasive tests	1	ITS	High*	-	-	-	-	Very low ⊕	No effect	CRITICAL
Costs	8	Compar ative	Low	High ***	Yes	High***	Unlikely	Very Low ⊕	No estimate	IMPORTANT
 ↓ miscarriages/adverse events of invasive test ↓ % end diagnostic process beyond 15 weeks ↓ anxiety) 	-	-	-	-	-	-	-	-	-	CRITICAL CRITICAL IMPORTANT
↓ Complexity of diagnostic process # Prevalence 0,563%										
 * Mixed definition of target ** Before and after study 			k)						ĺ	OSLO HTA

*** High variability in costs




Ethics and social context NIPT vs current practice




Third meeting: first vote

Q1. Replacement: Recommended median 8 RAND: agreement

Q2. Add-on (a)– median 5 RAND: strong disagreement



Combined-Test			N: 40 000			NIPT
-	+		(140 trisomies)		-	+
37 888 (FN 21)	2 112 (FP 1 99		Q1 Replacement		39 825 <mark>(FN 1)</mark>	
	↓					Ļ
	2 112 Invasive					175 Invasive tes
	119 triso	mies				139 trisomie
_					Combine	d-Test
	Combir	ned-Test		-		+
	-	+		37 888 <mark>(</mark> F	N 21)	2 112 <mark>(FP 1 993)</mark>
	37 888 (FN 21)	2 112 (FP 1 993)	Q2 Add-on			1
	(1 N 2 1)	(11 1 773)				NIPT
		2 112		-		+
		Invasive test		1 993 <mark>(</mark> F	N 2)	119 <mark>(FP 2)</mark>
		119 trisomies				Ţ
						119 Invasive test



Fourth meeting: Second Vote

100 % NIPT in replacement of Combined Test

NIPT in add-on to Combined test positive

NIPT not reccommended and waiting for further evidence

NIPT not reccommended





Conclusions



- Rapid response to Policy question
- Transparent and scientific method
- Consensus from a multidisciplinary panel

http://assr.regione.emilia-romagna.it **Thank you** 12th Annual Meeting